Amy Case
Chief Medical Officer Pulmonary Fibrosis Foundation
Dr. Amy Hajari Case is Chief Medical Officer of the Pulmonary Fibrosis Foundation and a leading voice in patient-centred care for interstitial lung disease. She serves as Director of the Interstitial Lung Disease Program and Pulmonary and Critical Care Research at Piedmont Healthcare, where she leads advanced lung disease initiatives and is principal investigator on multiple pulmonary fibrosis clinical trials.
Deeply committed to patient advocacy, Dr. Case has built nationally recognised ILD programmes, leads patient support groups, and drives education and awareness efforts across the pulmonary fibrosis community. A fellow of the American College of Chest Physicians and member of the American Thoracic Society, she is dedicated to expanding access to innovative therapies while improving outcomes and quality of life for patients living with pulmonary fibrosis.
Seminars
- Comparing commonly used IPF patient-reported outcome measures, including ERS-IPF, K-BILD, cough-specific instruments, and Living with IPF to understand their strengths, limitations, and clinical relevance
- Exploring why PRO use varies across trials, including regulatory expectations, endpoint selection, and differences in therapeutic mechanisms
- Discussing whether the field should move toward standardized PRO frameworks to better capture symptoms such as cough, breathlessness, fatigue, and overall quality of life
This session will examine how patient advocacy organizations are shaping IPF, PPF, and ILD drug development across the full development lifecycle, with a focus on trial design, regulatory engagement, reimbursement considerations, and sustained patient involvement.
- Explore how patient advocacy groups influence clinical trial design, enrolment strategies, and the selection of meaningful endpoints in IPF, PPF, and ILD studies
- Understand the role of patient organizations in shaping regulatory discussions and supporting access considerations for novel therapies
- Identify practical approaches for pharma to build effective, long-term partnerships with patient groups that extend beyond recruitment into ongoing engagement and advocacy
